Hypoparathyroidism Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Bridgebio/Calcil ytix Therapeutics, Ascendis Pharma, EnteraBio, Shire

The Key Hypoparathyroidism Companies in the market include - Ascendis Pharma, EnteraBio, Bridgebio/Calcil ytix Therapeutics, Shire, and others.

DelveInsight's "Hypoparathyroidism Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Hypoparathyroidism, historical and forecasted epidemiology as well as the Hypoparathyroidism market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Hypoparathyroidism market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hypoparathyroidism Market Forecast [https://www.delveinsight.com/sample-request/hypoparathyroidism-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Hypoparathyroidism Market Report:

*
The Hypoparathyroidism market size was valued USD 370 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

*
In September 2025, BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio"), a biopharmaceutical company specializing in genetic diseases, announced that encaleret achieved PTH-independent normalization of blood and urine calcium in patients with post-surgical hypoparathyroidism. The Phase 2 results were presented orally at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025.

*
In September 2025, MBX Biosciences is progressing its hypoparathyroidism therapy after 63% of patients met the primary endpoint in a Phase II trial. Following the announcement that once-weekly canvuparatide achieved this endpoint, the company's stock surged 100%, rising from $10.00 on September 19 to $20.00 on September 22. In the Phase II Avail trial (NCT06465108), 63% of patients treated with canvuparatide met the prespecified composite endpoint, maintaining normal albumin-adjusted serum calcium (8.2-10.6 mg/dL) and achieving independence from active vitamin D, over 600 mg/day calcium supplements, and PRN rescue therapy after 12 weeks, compared with 31% of placebo patients reaching the same outcome.

*
In May 2025, Bridgebio Pharma, in collaboration with its affiliate Calcilytix Therapeutics, reported that treatment with the investigational therapy encaleret normalized calcium levels in most participants with chronic hypoparathyroidism in a small proof-of-principle study. The company plans to initiate a clinical trial in 2026 that could support encaleret's approval for this condition. Hypoparathyroidism is characterized by abnormally low parathyroid hormone (PTH) levels, a hormone produced by the parathyroid glands that regulates calcium balance in the body. As a result, patients often experience hypocalcemia, or low calcium levels.

*
In March 2025, AstraZeneca's rare disease therapy has achieved the primary endpoint in a Phase III trial for patients with chronic hypoparathyroidism. In the Calypso trial (NCT05778071), eneboparatide, an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint, which assessed a composite of normalized albumin-adjusted serum calcium levels and independence from active vitamin D and oral calcium therapy. Key secondary endpoints included normalization of 24-hour urinary calcium in patients with baseline hypercalciuria and improvements in patient-reported outcomes.

*
In September 2024, Septerna, a clinical-stage biotechnology company leading the way in GPCR-targeted drug discovery, announced the initiation of dosing for the first participants in its Phase 1 clinical trial of SEP-786. This novel, potent, and selective oral small molecule parathyroid hormone 1 receptor (PTH1R) agonist is being developed to treat hypoparathyroidism. The Phase 1 trial, which includes both single-ascending dose (SAD) and multiple-ascending dose (MAD) cohorts, aims to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SEP-786 in healthy adult volunteers.

*
In May 2024, Amolyt Pharma has reported that the FDA has awarded fast track designation to eneboparatide, a drug developed for the treatment of hypoparathyroidism. This medication, currently undergoing assessment in the Phase III Calypso clinical trial, has demonstrated promise in previous studies by enhancing critical calcium levels and bone health. Results from the Phase III trial are anticipated to be disclosed next year, with the specific date yet to be determined.

*
In May 2024, Ascendis Pharma A/S (Nasdaq: ASND) has disclosed findings from a post-hoc analysis of the Phase 3 PaTHway Trial, showcasing significant and enduring enhancements in renal function among adults with chronic hypoparathyroidism treated with TransCon PTH (palopegteriparatide).

*
The overall population with hypoparathyroidism in the 7MM was approximately 284,000 in 2022 and is anticipated to rise by the year 2034.

*
Around 22,500 individuals were affected by Hypoparathyroidism in Japan in 2022. Forecasts indicate an expected rise in these cases from 2024 to 2034.

*
In the EU4 and the UK, the United Kingdom had the highest prevalence of hypoparathyroidism in 2022, with approximately 35,000 cases, surpassing Germany and France. In contrast, Spain recorded the lowest prevalent population of hypoparathyroidism.

*
Upcoming therapies for hypoparathyroidism that show significant promise include TransCon PTH by Ascendis Pharma, EB612 (PTH 1-34), and Encaleret by Bridgebio/Calcilytix Therapeutics.

*
Key Hypoparathyroidism Companies: Ascendis Pharma, EnteraBio, Bridgebio/Calcil ytix Therapeutics, Shire, and others

*
Key Hypoparathyroidism Therapies: TransCon PTH, Encaleret, rhPTH(1-84), EB612 (EBP05), NPSP558, and others

*
The Hypoparathyroidism epidemiology based on gender analyzed that Hypoparathyroidism affects females more than males.

*
The Hypoparathyroidism market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypoparathyroidism pipeline products will significantly revolutionize the Hypoparathyroidism market dynamics.

Hypoparathyroidism Overview

Hypoparathyroidism is a rare endocrine disorder characterized by insufficient levels of parathyroid hormone (PTH) in the body. PTH is produced by the parathyroid glands, which are located in the neck and are responsible for regulating calcium and phosphorus levels in the blood.

Get a Free sample for the Hypoparathyroidism Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/hypoparathyroidism-market [https://www.delveinsight.com/report-store/hypoparathyroidism-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hypoparathyroidism Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hypoparathyroidism Epidemiology Segmentation:

The Hypoparathyroidism market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Hypoparathyroidism

*
Prevalent Cases of Hypoparathyroidism by severity

*
Gender-specific Prevalence of Hypoparathyroidism

*
Diagnosed Cases of Episodic and Chronic Hypoparathyroidism

Download the report to understand which factors are driving Hypoparathyroidism epidemiology trends @ Hypoparathyroidism Epidemiology Forecast [https://www.delveinsight.com/sample-request/hypoparathyroidism-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hypoparathyroidism Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypoparathyroidism market or expected to get launched during the study period. The analysis covers Hypoparathyroidism market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hypoparathyroidism Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hypoparathyroidism Therapies and Key Companies

*
TransCon PTH: Ascendis Pharma

*
Encaleret: Bridgebio/Calcil ytix Therapeutics

*
rhPTH(1-84): Shire

*
EB612 (EBP05): Entera Bio Ltd.

*
NPSP558: Shire

Discover more about therapies set to grab major Hypoparathyroidism market share @ Hypoparathyroidism Treatment Landscape [https://www.delveinsight.com/sample-request/hypoparathyroidism-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hypoparathyroidism Market Strengths

*
Based on the route of administration, the parenteral method will remain the fastest-growing segment compared to oral methods.

*
Extensive cancer radiation treatment on the neck or face and new technology advancements for the treatment of hypoparathyroidism is set to further enhance the overall development of the hypoparathyroidism treatment market

Hypoparathyroidism Market Opportunities

*
In terms of drug class, calcium supplements might remain the most preferred in the coming future, with around 38% market share. PTH will also showcase a substantial growth rate.

*
Sales of hypoparathyroidism treatment drugs through retail pharmacies will generate maximum revenue, followed by hospital pharmacies.

Scope of the Hypoparathyroidism Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Hypoparathyroidism Companies: Ascendis Pharma, EnteraBio, Bridgebio/Calcil ytix Therapeutics, Shire, and others

*
Key Hypoparathyroidism Therapies: TransCon PTH, Encaleret, rhPTH(1-84), EB612 (EBP05), NPSP558, and others

*
Hypoparathyroidism Therapeutic Assessment: Hypoparathyroidism current marketed and Hypoparathyroidism emerging therapies

*
Hypoparathyroidism Market Dynamics: Hypoparathyroidism market drivers and Hypoparathyroidism market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Hypoparathyroidism Unmet Needs, KOL's views, Analyst's views, Hypoparathyroidism Market Access and Reimbursement

To know more about Hypoparathyroidism companies working in the treatment market, visit @ Hypoparathyroidism Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/hypoparathyroidism-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Hypoparathyroidism Market Report Introduction

2. Executive Summary for Hypoparathyroidism

3. SWOT analysis of Hypoparathyroidism

4. Hypoparathyroidism Patient Share (%) Overview at a Glance

5. Hypoparathyroidism Market Overview at a Glance

6. Hypoparathyroidism Disease Background and Overview

7. Hypoparathyroidism Epidemiology and Patient Population

8. Country-Specific Patient Population of Hypoparathyroidism

9. Hypoparathyroidism Current Treatment and Medical Practices

10. Hypoparathyroidism Unmet Needs

11. Hypoparathyroidism Emerging Therapies

12. Hypoparathyroidism Market Outlook

13. Country-Wise Hypoparathyroidism Market Analysis (2020-2034)

14. Hypoparathyroidism Market Access and Reimbursement of Therapies

15. Hypoparathyroidism Market Drivers

16. Hypoparathyroidism Market Barriers

17. Hypoparathyroidism Appendix

18. Hypoparathyroidism Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hypoparathyroidism-market-to-experience-notable-growth-in-forecast-span-by-2034-delveinsight-predicts-bridgebiocalcil-ytix-therapeutics-ascendis-pharma-enterabio-shire]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.